This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Morgan & Morgan Announces Investigation Of Chemed Corporation (CHE)

NEW YORK, Dec. 13, 2013 /PRNewswire/ -- Morgan & Morgan announces that it is investigating possible claims against the Board of Directors of Chemed Corporation ("Chemed") (NYSE: CHE) relating to alleged violations of the False Claims Act.

The United States Department of Justice (DOJ) filed a lawsuit in May of 2013 against Chemed and its affiliates alleging that Chemed defrauded Medicare by knowingly submitting false Medicare claims for hospice services that were either unnecessary, were not provided, or were provided to ineligible patients. Our investigation seeks to determine if the Chemed Board of Directors breached their fiduciary duties to shareholders in connection with the alleged violations cited by the DOJ.

If you own shares of Chemed and would like more information about the Chemed investigation, please contact George Pressly, Esq. at 1(800) 631-6234 or email George at AskGeorge@morgansecuritieslaw.com.

Morgan & Morgan is one of the nation's largest 200 law firms. In addition to securities fraud, the firm also practices in the areas of antitrust, personal injury, consumer protection, overtime, and product liability.  All of the Firm's legal endeavors are rooted in its core mission: provide investor and consumer protection and always fight "for the people." 

Attorney advertising. Prior results do not guarantee a similar outcome.

Contact:Morgan & Morgan Peter Safirstein, Esq.28 West 44th StreetSuite 2001 New York, NY  100361-800-631-6234 info@morgansecuritieslaw.com

SOURCE Morgan & Morgan

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs